Literature DB >> 27828863

The clinical characteristics of secondary primary tumors in patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy: A retrospective analysis.

Wei Zhao1, Hao Lei, Xiaodong Zhu, Ling Li, Song Qu, Xia Liang, Xiao Wang.   

Abstract

To investigate the clinical characteristics associated with the risk of developing secondary primary tumors (SPTs) in patients with nasopharyngeal carcinoma (NPC) who underwent intensity-modulated radiotherapy (IMRT).Data from 527 patients with biopsy-proven nonmetastatic NPC who were treated with IMRT between January 2007 and December 2011 were analyzed retrospectively. The cumulative incidence of SPTs after IMRT completion was estimated using the Kaplan-Meier method. Intergroup differences in the cumulative incidence were determined using the log-rank test. The Cox proportional hazards regression model was used to confirm the risk factors associated with IMRT-induced SPTs.The median follow-up duration was 45.5 months (range, 4-97 months). Of the 527 patients, 12 (2.3%) developed posttreatment SPTs (9 men, 3 women), 6 of which were located in the irradiation field. SPTs were mostly located in the upper aerodigestive tract (n = 7), head and neck (n = 6), lungs (n = 3), and tongue (n = 2). The 1-, 3-, and 5-year cumulative SPT risk rates were 0.4%, 1.4%, and 3.1%, respectively, and the mean annual growth in cumulative incidence was approximately 0.6%. The 1-, 3-, and 5-year cumulative in-field SPT risk rates were 0.4%, 0.8%, and 1.5%, respectively, and the mean annual growth in the in-field cumulative incidence was approximately 0.3%. Univariate and multivariate analysis revealed that sex, age, clinical stage, chemotherapy, and overall IMRT duration did not significantly affect SPT risk. However, the history of smoking was the independent risk factor associated with SPT.The 5-year SPT incidence among patients with NPC after IMRT is concordant with or lower than that in previous 2-dimensional radiotherapy studies study. Among patients with NPC who underwent IMRT, the upper aerodigestive tract was the most common SPT site, and lung cancer was the most common pathology. Smoking history, but not sex, age, clinical stage, chemotherapy, and overall IMRT duration is the independent risk factor associated with SPT. Additional large-scale studies with longer-term follow-ups are needed to determine risk factors associated with SPT development after IMRT.

Entities:  

Mesh:

Year:  2016        PMID: 27828863      PMCID: PMC5106069          DOI: 10.1097/MD.0000000000005364

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  30 in total

1.  Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment.

Authors:  A J Swerdlow; M J Schoemaker; R Allerton; A Horwich; J A Barber; D Cunningham; T A Lister; A Z Rohatiner; G Vaughan Hudson; M V Williams; D C Linch
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

2.  Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries.

Authors:  Amy Berrington de González; Sarah Darby
Journal:  Lancet       Date:  2004-01-31       Impact factor: 79.321

3.  Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery.

Authors:  D J Brenner; R E Curtis; E J Hall; E Ron
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

4.  Increased incidence of tongue cancer after primary radiotherapy for nasopharyngeal carcinoma--the possibility of radiation carcinogenesis.

Authors:  P M Teo; A T Chan; S F Leung; R M Chau; P K Yu; W W King; P J Johnson
Journal:  Eur J Cancer       Date:  1999-02       Impact factor: 9.162

5.  The relationship of nasopharyngeal carcinomas and second independent malignancies based on the Radiation Therapy Oncology Group experience.

Authors:  J S Cooper; C Scott; V Marcial; T Griffin; J Fazekas; G Laramore; A Hoffman
Journal:  Cancer       Date:  1991-03-15       Impact factor: 6.860

6.  Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region.

Authors:  D Verellen; F Vanhavere
Journal:  Radiother Oncol       Date:  1999-12       Impact factor: 6.280

Review 7.  Radiation-induced second cancers: the impact of 3D-CRT and IMRT.

Authors:  Eric J Hall; Cheng-Shie Wuu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

8.  Breast cancer after treatment of Hodgkin's disease.

Authors:  S L Hancock; M A Tucker; R T Hoppe
Journal:  J Natl Cancer Inst       Date:  1993-01-06       Impact factor: 13.506

9.  Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries.

Authors:  Shu-Chun Chuang; Ghislaine Scelo; Jon M Tonita; Sharon Tamaro; Jon G Jonasson; Erich V Kliewer; Kari Hemminki; Elisabete Weiderpass; Eero Pukkala; Elizabeth Tracey; Soren Friis; Vera Pompe-Kirn; David H Brewster; Carmen Martos; Kee-Seng Chia; Paolo Boffetta; Paul Brennan; Mia Hashibe
Journal:  Int J Cancer       Date:  2008-11-15       Impact factor: 7.396

Review 10.  Myelodysplastic syndrome after cisplatin therapy.

Authors:  R Cheruku; M Hussain; M Tyrkus; M Edelstein
Journal:  Cancer       Date:  1993-07-01       Impact factor: 6.860

View more
  3 in total

Review 1.  Secondary Oral Cancer after Systemic Treatment of Hematological Malignancies and Oral GVHD: A Systematic Review.

Authors:  Aleksandra Janowiak-Majeranowska; Jakub Osowski; Bogusław Mikaszewski; Alan Majeranowski
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

2.  Secondary Squamous Cell Carcinoma of the Oral Cavity after Nasopharyngeal Carcinoma.

Authors:  Liyuan Dai; Qigen Fang; Peng Li; Junfu Wu; Xu Zhang
Journal:  Cancer Res Treat       Date:  2019-05-30       Impact factor: 4.679

3.  Second Primary Lung Adenocarcinoma After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma.

Authors:  Fen Xue; Xiaoshuang Niu; Chaosu Hu; Xiayun He
Journal:  Front Oncol       Date:  2022-02-24       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.